Related Experiment Video
Updated: Apr 22, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Lessons from patient-derived xenografts for better in vitro modeling of human cancer
Stephen Yiu Chuen Choi1, Dong Lin1, Peter W Gout2
1Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC, Canada; Vancouver Prostate Centre, Vancouver, BC, Canada.
Abstract:
The development of novel cancer therapeutics is often plagued by discrepancies between drug efficacies obtained in preclinical studies and outcomes of clinical trials. The inconsistencies can be attributed to a lack of clinical relevance of the cancer models used for drug testing. While commonly used in vitro culture systems are advantageous for addressing specific experimental questions, they are often gross, fidelity-lacking simplifications that largely ignore the heterogeneity of cancers as well as the complexity of the tumor microenvironment. Factors such as tumor architecture, interactions among cancer cells and between cancer and stromal cells, and an acidic tumor microenvironment are critical characteristics observed in patient-derived cancer xenograft models and in the clinic. By mimicking these crucial in vivo characteristics through use of 3D cultures, co-culture systems and acidic culture conditions, an in vitro cancer model/microenvironment that is more physiologically relevant may be engineered to produce results more readily applicable to the clinic.
Insights
Developing more clinically relevant cancer models is crucial for effective drug discovery. Mimicking in vivo conditions in 3D cultures can improve preclinical cancer drug testing accuracy.
Area of Science:
- Oncology
- Biomedical Engineering
- Drug Discovery
Background:
- Preclinical cancer drug efficacy often fails to translate to clinical trials.
- Current in vitro models lack the complexity and heterogeneity of human tumors and their microenvironments.
- Tumor architecture, cell-cell interactions, and acidic pH are key in vivo features often missing in standard cell cultures.
Purpose of the Study:
- To address the discrepancy between preclinical drug testing and clinical outcomes.
- To engineer more physiologically relevant in vitro cancer models.
- To improve the predictive power of cancer models for therapeutic development.
Main Methods:
- Utilizing 3D cell cultures to replicate tumor architecture.
- Implementing co-culture systems to model cancer cell-stromal cell interactions.
- Applying acidic culture conditions to mimic the tumor microenvironment's pH.
Main Results:
- Engineered in vitro models better recapitulate in vivo tumor characteristics.
- The developed models incorporate tumor heterogeneity and microenvironmental complexity.
- These advanced models offer a more accurate platform for preclinical drug evaluation.
Conclusions:
- Physiologically relevant in vitro cancer models are essential for successful drug development.
- Mimicking in vivo features like 3D structure, cell interactions, and acidity enhances model fidelity.
- Improved preclinical models can lead to more effective cancer therapeutics in clinical settings.
More Related Videos
05:33Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
04:49Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
Published on: May 5, 2021